Oncolytics Biotech Inc.Oncolytics Biotech (NASDAQ:ONCY / TSX:ONC) announced that positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer will be presented at ASCO. The BRACELET-1 (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 and Paclitaxel) is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement with Pfizer Inc. (NYSE:PFE) and Merck KGaA, Darmstadt, Germany. The ASCO annual meeting will be held in Chicago from June 2 to 6, 2023. To find out more about Oncolytics study that will be featured at the event, click here. IMO very positive events happening which will likely afford the opportunity for ONC to either form a partnership and or a complete buyout. Just sayin:)